Brief: Imugene Says FDA Fast Track Designation Granted For CF33-HNIS (Vaxinia) Mast Clinical Program
28/11/2023 01:42
Nov 28 (Reuters) - Imugene Ltd IMU.AX :
* FDA FAST TRACK DESIGNATION FOR BILE DUCT CANCER GRANTED
FOR
CF33-HNIS (VAXINIA) MAST CLINICAL PROGRAM
Source text for Eikon: ID:nASXhzV60
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement